A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
DSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
“, OPRM1 A118G and naltrexone response [124, 125]) Positron emission tomography (PET) imaging of brain functioning indicates that dopamine is associated with substance use (126, 127).”
BackgroundSelf-citationOpioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Should addictive disorders include non-substance-related conditions?
Potenza, M. N. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01591.x · Cited by 663
“As genetic factors have been associated with positive outcome for treatment of SUDs [81], genetic sampling should be considered in treatment trials in PG and other ICDs.”
BackgroundAlcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
The behavioral economics of substance use disorders: reinforcement pathologies and their repair
Bickel, W. K., Johnson, M. W., Koffarnus, M. N., MacKillop, J., & Murphy, J. G. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153724 · Cited by 655
“…a single nucleotide polymorphism in the OPRM1 gene (rs1799971) is associated with greater sensitivity to alcohol’s subjective effects (Ray & Hutchison 2004, 2007) and naltrexone’s clinical effects (Anton et al. 2008, Kim et al. 2009, Oslin et al. 2003), participants were genotyped for this locus.”
Background
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients. https://app.cochat.ai/papers/10.1038/sj.npp.1300219
- The paper
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003). A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1300219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.